Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Simon L Porter"'
Autor:
John F. Callan, Barry O'Hagan, Nikolitsa Nomikou, Paul J Kelly, Bridgeen Callan, Simon L Porter, Eva McMullin, Dean Nicholas, Declan O'Rourke, Anthony P. McHale, Sian Farrell, Tierna Gillan, Heather Nesbitt, Keith Thomas, Keirin Logan
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 163:49-59
Sonodynamic therapy (SDT) is an emerging stimulus-responsive approach for the targeted treatment of solid tumours. However, its ability to generate stimulus-responsive cytotoxic reactive oxygen species (ROS), is compromised by tumour hypoxia. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec05b0a0b74b3c65d17998bf0ae7a266
https://doi.org/10.1016/j.ejpb.2021.03.005
https://doi.org/10.1016/j.ejpb.2021.03.005
Autor:
Kathyrn Burnett, Nermeen Rizk, Heather Nesbitt, Anthony P. McHale, Thomas McKaig, Bridgeen Callan, Yingjie Sheng, Simon L Porter, Simanpreet Kaur Dhillon, Rubeta N Matin, Bronagh White, John F. Callan
Publikováno v:
Journal of Medicinal Chemistry. 63:1328-1336
Malignant melanoma is an aggressive skin cancer with poor survival outcomes for patients diagnosed at an advanced stage. While targeted serine/threonine-protein kinase B-Raf (BRAF) and immune checkpoint inhibitors have improved survival outcomes for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a57ee9fe1db73370e1560a85705765
https://doi.org/10.1021/acs.jmedchem.9b01802
https://doi.org/10.1021/acs.jmedchem.9b01802
Publikováno v:
Gels, Vol 4, Iss 2, p 48 (2018)
The threat of antimicrobial resistance to society is compounded by a relative lack of new clinically effective licensed therapies reaching patients over the past three decades. This has been particularly problematic within antifungal drug development
Externí odkaz:
https://doaj.org/article/2cc4377ea9b04ddb9c312ab574958aab
Publikováno v:
Journal of chemical information and modeling. 53(7)
Selective polypharmacology, where a drug acts on multiple rather than a single molecular target involved in a disease, emerges to develop a structure-based system biology approach to design drugs selectively targeting a disease-active protein network
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327e15aadcc2830f18dd67e896874224
https://pubmed.ncbi.nlm.nih.gov/23789628
https://pubmed.ncbi.nlm.nih.gov/23789628